Keyphrases
Chronic Myeloid Leukemia
100%
Tyrosine Kinase Inhibitor
100%
Immune Thrombocytopenia
100%
Hematopoietic Stem Cell Transplantation
75%
Myelosuppression
50%
Quality of Life
25%
Late Events
25%
Dose Effect
25%
Leukemia Patients
25%
Thrombocytopenia
25%
Late Development
25%
Intolerance
25%
Imatinib Therapy
25%
Salvage Therapy
25%
Severe Thrombocytopenia
25%
Anti-platelet Antibodies
25%
Second-generation Tyrosine Kinase Inhibitors
25%
Tyrosine Kinase Inhibitor Resistance
25%
Medicine and Dentistry
Tyrosine-Kinase Inhibitor
100%
Chronic Myelogenous Leukemia
100%
Idiopathic Thrombocytopenic Purpura
100%
Hematopoietic Stem Cell Transplantation
50%
Thrombocytopenia
33%
Bone Marrow Suppression
33%
Quality of Life
16%
Myeloid Leukemia
16%
Imatinib
16%
Salvage Therapy
16%
Thrombocyte Antibody
16%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Myeloid Leukemia
100%
Idiopathic Thrombocytopenic Purpura
100%
Protein Tyrosine Kinase Inhibitor
100%
Thrombocytopenia
33%
Bone Marrow Suppression
33%
Imatinib
16%
Myeloid Leukemia
16%
Thrombocyte Antibody
16%